Cargando…
Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2
MAPK-activated protein kinase 2 (MK2) is a checkpoint kinase involved in the DNA damage response. MK2 inhibition enhances the efficacy of chemotherapeutic agents; however, whether MK2 inhibition alone, without concurrent chemotherapy, would attenuate survival of cancer cells has not been investigate...
Autores principales: | Gurgis, FMS, Åkerfeldt, MC, Heng, B, Wong, C, Adams, S, Guillemin, GJ, Johns, TG, Chircop, M, Munoz, L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979411/ https://www.ncbi.nlm.nih.gov/pubmed/27551460 http://dx.doi.org/10.1038/cddiscovery.2015.28 |
Ejemplares similares
-
MK2a inhibitor CMPD1 abrogates chikungunya virus infection by modulating actin remodeling pathway
por: Mamidi, Prabhudutta, et al.
Publicado: (2021) -
MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma Cells
por: Phoa, Athena F., et al.
Publicado: (2020) -
Deciphering the true antiproliferative target of an MK2 activation inhibitor in glioblastoma
por: Brennan, P E
Publicado: (2016) -
Promyelocytic leukemia protein targets MK2 to promote cytotoxicity
por: Chen, I‐Ting, et al.
Publicado: (2021) -
The acid–base and redox properties of menaquinone MK-4, MK-7, and MK-9 (vitamin K(2)) in DMPC monolayers on mercury
por: Dharmaraj, Karuppasamy, et al.
Publicado: (2020)